Epstein Secrets

otic disease should discuss their LDL cholesterol with their physician and consider whether they need to lower it further." Reference Sabatine MS. Giugliano RP, Keech AC, et al. N Engl J Med. 2017;doi:NEJMoa1615664 http://www.nejm.orq/doUpdf/10.1056/NEJMoa 1615664 Sabatine M. Primary Results of the Further

uction with Evolocumab Reply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2

otic disease should discuss their LDL cholesterol with their physician and consider whether they need to lower it further." Reference Sabatine MS, Giugliano RP, Keech AC, et al. N Eng! J Med. 2017;doi:NEJMoa1615664 http://www.nejm.orgidoi/pdf/10.1056/NEJMoa1615664 Sabatine M. Primary Results of the Further

cumab Reply-To: Cardiology Alert < EFTA00447987 Entail not displaying coirectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2

otic disease should discuss their LDL cholesterol with their physician and consider whether they need to lower it further." Reference Sabatine MS, Giugliano RP, Keech AC, et al. N Eng! J Med. 2017;doi:NEJMoa1615664 http://www.ne m.orgidoi/pdftl0.1056/NEJMoa1615664 Sabatine M. Primary Results of the Further

eduction with Evolocumab Reply-To: Cardiology Alert E— ail not displaying conectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2